S anofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Armed with new nods in asthma and adolescent eczema, Regeneron’s Dupixent keeps reeling in new biologics patients. But as phase 3 results in COPD loom, helmsman Len Schleifer warns that tapping into ...

The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is a rare and aggressive form of cancer that has been linked to the drug Dupixent in some cases.

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...